

Communiqué from the annual general meeting of AcouSort AB (publ)

Today, April 30, 2024, the annual general meeting was held in AcouSort AB (publ). Below is a summary of the decisions that were made. All decisions were made with the required majority.

Profit allocation and decision on discharge from liability.

The meeting approved the income statement and balance sheet for both the parent company and the group. The meeting decided to dispose of the company's results according to the board's proposal in the annual report. The meeting further decided that no dividend will be paid for the financial year 2023. In addition, the meeting decided to discharge the members of the board and the CEO for the financial year 2023.

Determining the fees for the board and auditor

The meeting decided that the board should consist of four board members and no board deputy, and that no remuneration should be paid to the board. Furthermore, the meeting decided that an auditor and no deputy auditor shall be appointed, and that fees to the auditor shall be paid according to an approved bill in accordance with customary billing standards.

Election of the board and auditor

The meeting decided that Thomas Laurell, Stefan Scheduling, Martin Olin and Katherine Flagg are re-elected as board members. Martin Olin was re-elected chairman of the board. Furthermore, the meeting decided that the company's auditor Öhrlings PricewaterhouseCoopers AB, with Mikael A Nilsson as chief auditor, be re-elected until the end of the annual general meeting held next financial year.

Decision on authorization for the board to issue shares, convertibles or warrants with preferential rights for the company's shareholders.

The annual general meeting approved the board's proposal for authorization for the board to, on one or more occasions before the next annual general meeting, within the limits of the articles of association, only with preferential rights for the company's shareholders, decide on new issue of shares or issue of convertibles or warrants. Issuance must be possible against cash payment or set-off.

Decision on authorization for the board to issue shares, convertibles or warrants without preferential rights for the company's shareholders.

The annual general meeting approved the board's proposal to authorize the board to decide on a new issue of shares or issue of convertibles or warrants on one or more occasions before the next annual general meeting, deviating from the shareholders' pre-emptive rights. The authorization is limited in such a way that the number of shares, after a fully subscribed new issue, full utilization of warrants or full conversion, does not increase by more than fifteen (15) percent of the number of shares outstanding at the time of this meeting.

Miscellaneous

The meeting decided to authorize the board, or whoever the board appoints, to carry out the minor adjustments that prove necessary when registering the decisions.



PRESS RELEASE

30 April 2024 09:55:00 CEST

Lund in April 2024
AcouSort AB (publ)
THE BOARD OF DIRECTORS

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).